Archives: Agenda

With a disproportionately large number of patients willing to participate in global studies, Canada’s world-class researchers and diverse patient population, trial cost efficiency, robust health authority with reliable process times, consistent data quality, and national therapeutic expertise in oncology make it an attractive country for enrollment to your global clinical trial program.

This presentation explores how to succeed with your oncology trial in Canada with insights on:

• The Perception Gap
• How Sponsors Receive: Predictability. Speed. Quality. Partner Accountability
• Competitive Structural Advantages
• Real-World Global Trial Examples
• What to Expect in a Partner for the Region

• Tackling challenges in cell therapy study design to reduce timelines and ensure quality and relevance for the field
• Partnering effectively with CROs: what constitutes a productive collaboration in the cell therapy space
• Logistics in cell therapy: challenges and solutions

How strategic collaboration can accelerate innovation:

• Moving from transactional execution to consultative partnership
• How CROs can become strategic problem solvers, not just service providers
• Building trust transparency and shared accountability

• Keeping compliant with evolving global, regional, and local regulation to minimize timelines and avoid costly delays
• Overviewing new regulation and assessing the impact on conducting oncology clinical trials
• Ensuring vendor oversight to ensure regulatory compliance for smooth running of oncology clinical trials
• Considering Project Optimus early in development programs to keep in line with regulatory demands

The AI Advantage in Insurance: Winning On Customer Experience

• Where AI is delivering real CX results
• Reduce churn & boost retention
• Personalised, digital-first journeys

Allan Christian
General Manager
Engage

• Navigating the VC & strategic investment landscape: Understanding fund priorities, timing, and risk thresholds to position your trial and company for maximum appeal amid intense competition for limited budgets
• Crafting a compelling narrative, highlighting niche advantages, and strengthening your pipeline to secure funding partnerships that bridge financial gaps and accelerate oncology innovation
• How adaptive designs, decentralized elements, synthetic control arms, and AI-driven efficiencies can make oncology studies more capital-efficient and more attractive to venture capital and strategic investors
• Avoiding bankruptcy risk for biotechs with clear early efficacy signals, validated biomarkers and programs with strong regulatory alignment

• Traditional segmentation still matters—but it’s not enough
• The no-alcohol opportunity is much bigger than it looks
• Who are non-alcohol consumers? Let’s go beyond the surface
• Better taste match directly translates into higher value share